
-
Catalyst Pharmaceutical NasdaqCM:CPRX Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Location: 355 Alhambra Circle, Coral Gables, FL, 33134, United States | Website: https://catalystpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.421B
Cash
580.7M
Avg Qtr Burn
N/A
Short % of Float
6.58%
Insider Ownership
6.28%
Institutional Own.
83.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FIRDAPSE®(Amifampridine) Details Lamber-Eaton myasthenic syndrome | Approved Quarterly sales | |
AGAMREE® (Vamorolone) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
FIRDAPSE®(Amifampridine) Details Autoimmune disease, Lamber-Eaton myasthenic syndrome | Approved Quarterly sales | |
FYCOMPA Details Epilepsy | Approved Quarterly sales | |
FIRDAPSE® (Amifampridine) Details Autoimmune disease, Neuromuscular disease | Failed Discontinued |